Could This Recently IPOed Medical Device Maker Make You Rich?
NeuroPace (NASDAQ: NPCE), is growing the implantable device market for treating drug-resistant focal epilepsy and setting itself up to dominate it for years to come. With an offering that provides better outcomes than its competition, significant penetration into epilepsy centers across the U.S., and potential label expansions that could just about double its current addressable market, this company could offer significant upside to investors.
NeuroPace makes a $50,000 implantable device, the RNS (Responsive Neurostimulation) System, that continuously monitors epilepsy patients' brain activity and responds to patient-specific seizure patterns. This allows for personalized, targeted, and data-driven treatment.
Currently, the RNS System is only approved for adults with drug-resistant focal epilepsy. But the $590 million market cap company believes it's sitting on a $26 billion addressable market in the U.S. alone. Even better, it believes that if its device's approval is expanded to include patients under 18, as well as patients with generalized drug-resistant epilepsy, its addressable market could double.
Source Fool.com
